Valuation: Moderna, Inc.

Market Cap 31.65B 27.7B 25.53B 23.66B 44.91B 3,004B 45.64B 306B 119B 1,483B 119B 116B 5,124B P/E 2026 *
-9.21x
P/E 2027 * -16.8x
Enterprise Value 28.05B 24.54B 22.62B 20.96B 39.8B 2,662B 40.44B 271B 105B 1,314B 105B 103B 4,541B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 11.5x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-39.82% - - 32.46B
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
+0.29%+8.28%-49.90%-53.45% 41.28B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
+0.17%+9.80%+5.88%+188.93% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
+0.21%+4.61%+79.10%+361.28% 15.23B
Average +0.74%+3.96%+39.29%+106.83% 34.61B
Weighted average by Cap. +1.06%+3.53%+32.67%+79.45%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.56B 2.97B 198B 3.01B 20.22B 7.86B 97.94B 7.85B 7.68B 339B 2.54B 2.23B 2.05B 1.9B 3.61B 241B 3.67B 24.61B 9.57B 119B 9.55B 9.35B 412B
Net income -3.41B -2.98B -2.75B -2.55B -4.84B -324B -4.92B -32.98B -12.83B -160B -12.8B -12.53B -552B -1.85B -1.62B -1.49B -1.38B -2.63B -176B -2.67B -17.89B -6.96B -86.66B -6.95B -6.8B -300B
Net Debt -3.61B -3.16B -2.91B -2.7B -5.12B -342B -5.2B -34.87B -13.56B -169B -13.54B -13.24B -584B -2.27B -1.99B -1.83B -1.7B -3.23B -216B -3.28B -22B -8.56B -107B -8.54B -8.36B -368B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB